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p63 expression in sarcomatoid/metaplastic
carcinomas of the breast
Sir: In the paper by Kurian and Al-Nafussi,1 describing
a series of sarcomatoid ⁄ metaplastic carcinoma of the
breast, the authors stress the difficulties in differenti-
ating a bona fide case of monophasic sarcomatoid
tumour of the breast from its mimics, such as phyllodes
tumours or breast sarcomas.1 Briefly, the role of
immunohistochemical markers, such as low molecular
weight cytokeratins and epithelial membrane antigen,
in the recognition of these rather unusual and tricky
neoplasms was emphasized.1 We would like to add
some promising data regarding p63, a novel
basal ⁄ myoepithelial cell immunohistochemical marker
that may help in this differential diagnosis and may
also give new insights on the histogenesis and differ-
entiation of sarcomatoid ⁄ metaplastic carcinomas of
the breast.
We have been analysing p63 (clone 4A4, dilution
1:150; Neomarkers, Freemont, CA, USA) expression in
several types of breast neoplasms.2 p63 is a p53
homologue whose gene is located on 3q27.2,3 At
variance with p53 gene, which encodes an unique
53-kDa protein, p63 gene encodes six isoforms which
differ in the C-terminal (a, b, and c) and in the
N-terminal (transactivating and DN-isoforms).2,3 While
TA-isoforms are able to promote the transcription of
p53-reporting genes, DN-isoforms are unable to do
so.2–4 Interestingly, DN-isoforms are consistently
expressed in the nuclei of myoepithelial ⁄ basal cells of
the breast, as well as in basal cells of several multi-
layered epithelia2–4 which may be an alternative
mechanism to overcome p53-driven cell cycle arrest
and apoptosis.2–4
We2 and others4–6 have observed a strong and
diffuse p63 expression in the nuclei of normal myoepi-
thelial cells of breast lobules and ducts, as well as in the
cells of myoepithelial tumours, such as sclerosing
papilloma, adenomyoepithelioma, adenoid-cystic car-
cinoma, epithelial-myoepithelial carcinoma and malig-
nant adenomyoepithelioma.2,4 Interestingly, we2 and
others4,5 also observed p63 expression in cases of
monophasic sarcomatoid ⁄ metaplastic carcinomas of
the breast. An eye-catching feature was a rather strong
and consistent p63 expression in the nuclei of spindle
and epithelioid neoplastic cells in bona fide cases of
mono- and biphasic sarcomatoid ⁄ metaplastic carcin-
omas of the breast (Figure 1). The majority of these
cells also co-expressed cytokeratins; however, some
spindle cells showed p63 expression only. p63 seems to
be a good myoepithelial marker, because stromal cells,
fibroblasts, and myofibroblasts observed in normal
breast, fibromatoses, fibroadenomas and phyllodes
tumours fail to express p63, as observed by our
group (Reis Filho et al., manuscript submitted) and
Barbareschi et al.4
p63 expression in normal breast tissue and neoplasms
of the breast is not a fully characterized phenomenon.
Based on double-immunostaining studies, the expres-
sion of p63 and smooth-muscle markers, such as
a-smooth muscle actin, calponin, and smooth muscle
myosin heavy chain, Barbareschi et al.4 demonstrated
that a subset of p63+ cells co-express smooth-muscle
markers, while others do not. The p63+ smooth-muscle
marker-positive phenotype probably represents the
usual immunophenotype of myoepithelial cells, while
p63+ smooth-muscle marker-negative is probably what
could be expected to be expressed by basal cells.2,4
The presence of p63 immunoreactivity seems to point
Figure 1. Medium power magnification of a monophasic and bland-
looking sarcomatoid ⁄ metaplastic carcinoma of the breast. A, Note
the presence of myxoid areas and the deceiving bland appearance
of the cells (H&E). B, p63 immunostaining highlighting the nuclei
of neoplastic cells arranged in strands and cords. (Streptavidin–
biotin–peroxidase ⁄ DAB.)
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towards a putative myoepithelial ⁄ basal cell histogenesis ⁄
differentiation in some types of sarcomatoid ⁄ meta-
plastic carcinomas of the breast.2,4,5
Based on our preliminary results2 and on Barbare-
schi et al.4 and Wang et al.5 findings, we would like to
stress that p63 might be included in immunohisto-
chemical panels designed to diagnose peculiar breast
neoplasms that putatively show a myoepithelial histo-
genesis. p63 may also play a major role in the
diagnosis of sarcomatoid ⁄ metaplastic carcinomas of
the breast, because it is consistently expressed in these
tumours.2 Moreover, these findings warrant that the
role of p63 pathway should be investigated in neo-
plasms showing a basal ⁄ myoepithelial cell immuno-
phenotype, because it seems that tumours with a basal
cell phenotype are associated with an aggressive
behaviour7 and that DN-p63 over-expression might
be an alternative mechanism to overcome p53 tumour
suppressor functions.
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Sex hormone receptor immunohistochemis-
try staining in Barrett’s oesophagus
and adenocarcinoma
Sir: The incidence of oesophageal adenocarcinoma is
rising,1 both relative to squamous carcinoma and in
absolute terms. Barrett’s oesophagus2 is thought to be
the principal risk factor for this cancer. Whilst the
gender ratio of uncomplicated reflux disease is approxi-
mately equal, male patients with Barrett’s oesophagus
more frequently develop oesophageal adenocarcinoma.3
We have therefore investigated the expression of both
oestrogen and androgen receptors in patients who
had Barrett’s oesophagus and adenocarcinoma of the
oesophagus.
We retrieved archived paraffin blocks from 10 male
(38–77 years) and 10 female (29–90 years) patients in
whom there was Barrett’s oesophagus with intestinal
metaplasia and adenocarcinoma. From these, 4-lm
APES sections were taken and stained with androgen
receptor (AR) and oestrogen receptor (ER) antibodies
according to the manufacturer’s (Dako UK Ltd, Ely,
Cambridgeshire, UK) instructions. Control tissues from
breast and prostate carcinoma were used for validation.
The sections were scored independently by two pathol-
ogists, and where there was disagreement a consensus
score was agreed. Staining was quantified in terms of
both the intestinal metaplasia and carcinoma elements
using a scale of absent ⁄ mild ⁄ moderate ⁄ heavy staining.
Androgen receptor staining was very weakly positive
in one male adenocarcinoma and one female intestinal
metaplasia case, with the remainder showing no
staining. Oestrogen receptor staining was seen in four
cases of male intestinal metaplasia, two cases of
male adenocarcinoma, four cases of female intestinal
metaplasia and six cases of female adenocarcinoma.
These showed mild–moderate staining. The remaining
cases were negative for ER.
The results from this limited sample of cases suggest
that androgen receptors are not implicated in Barrett’s
oesophagus or adenocarcinoma. The role of oestrogen
receptors may merit further investigation. However, a
previous study by Lagergren and Nyren4 showed that
hormonal manipulation (principally oestrogen therapy)
in prostate cancer patients did not alter the incidence of
oesophageal adenocarcinoma in this study population.
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